Immunotherapy retrial with cromolyn and bispecific antibodies for breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new combination of drugs for triple negative breast cancer that has worsened after prior immunotherapy. The goal is to see if these treatments can shrink tumors and help patients who have not responded to earlier immunotherapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- You have triple negative breast cancer that has spread or come back.
- You have already had immunotherapy treatment that stopped working.
- You have at least one tumor that can be measured on a scan.
- Your organs (like bone marrow, liver, and kidneys) are working well enough based on blood tests.
- You are willing to use birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This trial tests a new combination of two immunotherapy drugs (INBRX-106 and pembrolizumab) given before surgery for people with early-stage triple-negative breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a new combination of targeted chemotherapy (sacituzumab govitecan) with immunotherapy (pembrolizumab) against standard chemotherapy for people with triple-negative breast cancer that has not spread. It is for those who have already started a specific chemotherapy and immunotherapy regimen and may qualify if their cancer is stage II or III.
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
This trial tests a new combination of three drugs (cyclophosphamide, axatilimab, and retifanlimab) for people with metastatic triple negative breast cancer. The goal is to see if adding a low dose of chemotherapy can make the immunotherapy work better.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.